

August 2, 2022

On June 24, 2022, the US Food and Drug Administration issued a draft guidance document on the <u>Considerations for Rescinding Breakthrough Therapy Designation</u>. The guidance explains how the FDA may rescind a drug or biologic candidate's breakthrough therapy designation during its development (this guidance does **not** apply to medical devices¹). The agency is accepting <u>public comments on this guidance</u> through August 23, 2022.

What is breakthrough therapy designation (BTD)?

BTD is an FDA expedited drug development program under the Federal Food, Drug, and Cosmetic Act, 21 USC 356(a), for drug candidates with preliminary clinical evidence for potentially substantial improvement over existing therapies to treat a serious or life-threatening disease or condition. A sponsor of a BTD drug will have meetings with and timely advice from the FDA review team throughout the development process, and the FDA has committed resources to expedite the review of the marketing application of the drug, including rolling review. Although a sponsor may request BTD for its drug candidate concurrently with the submission of an Investigational New Drug (IND) application, according to a 2014 guidance on expedited programs, the FDA generally expects the required preliminary clinical evidence to be derived from phase 1 or 2 trials, ideally from comparison studies with a sufficient number of patient subjects. The FDA also expects a BTD request to be submitted before the end-of-phase 2 meeting.²

FDA can rescind BTD

While the FDA can grant BTD to qualified drug candidates, it can also take it away. During the development process, sponsors generate new data and information, and the clinical evidence supporting BTD may change. According to the 2014 guidance, the FDA periodically assesses BTD drug candidates, and if the agency determines that a candidate no longer meets the criteria for BTD, it may rescind the designation to save the resources for other qualified drugs. The FDA will offer the sponsor an opportunity to oppose to its rescission decision. Upon receiving notice of the FDA's intent to rescind BTD, the sponsor may request a meeting with the FDA and voluntarily withdraw, rather than force rescission of the BTD in a process known as Withdrawn After Granting (WAG). Each year, more sponsors face rescission rather than voluntarily withdrawing through the WAG process.

The 2014 guidance did not provide details on how the FDA makes a rescission decision, but the current draft guidance offers numerous scenarios in which the FDA will consider rescinding a BTD, including:

- As a result of a newly approved drug, where the BTD drug no longer meets the BTD criteria regarding substantial improvement over existing available therapies.
- When emerging data for the BTD drug does not support the designation (e.g., a phase 3 trial failing to meet its primary endpoint, or new safety information impacting the drug's benefit-risk profile).
- If the sponsor is no longer pursuing the drug's development.

The FDA considers the quality of evidence in determining whether BTD recission is appropriate. For example, the agency gives greater weight to data from trials with larger populations, a well-understood and widely accepted, well-constructed clinical endpoint, or other robust design features (e.g., randomization, blinding).


Overview of other expedited programs

Besides BTD, the FDA offers three other expedited programs for drug candidates (including biological products) intended to treat serious or life-threatening diseases or conditions:

- Fast track designation is given to drug candidates with nonclinical or clinical data that may demonstrate the potential to address an unmet medical need to treat a serious condition, or to qualified infectious disease drugs. Features of the program include frequent interactions with the review team and rolling review. The FDA may rescind the designation if the qualifying criteria is no longer met. The key difference between fast track designation and BTD is that fast track designation does not require clinical evidence, which means that sponsors could obtain fast track designation earlier in the development process.
- Accelerated approval pathway is for drugs with a meaningful advantage over available therapies to treat a serious condition, based on a demonstrated effect on surrogate or intermediate endpoints.³
- Priority review designation is given to marketing applications for drug candidates that can provide a significant
 improvement in treating a serious condition or under certain other conditions. The FDA intends to take action on such
 applications within six months of receipt, instead of the standard 10 months generally required for review.⁴

A sponsor may apply for all four expedited programs for its drug candidate, and should reach out to regulatory counsel to discuss the advantages and potential benefits each program may provide for a particular development program. The timeline below summarizes when to submit requests for each of the expedited programs.

Accelerated approval (communicate with the FDA early in development)



Considerations

The expedited programs can provide invaluable regulatory tools for pharmaceutical and biotech companies because they can help bring a drug or biological product to market faster or in a more cost-efficient way. The FDA's draft guidance serves as a good reminder that once given, these designations are not set in stone. If you are considering an expedited program for your drug candidate or suspect that the FDA may rescind a previously awarded designation, reach out to your Cooley team for assistance.

Cooley summer associate Sarah Miller also contributed to this alert.

Notes

- 1. For medical devices, the FDA grants breakthrough devices designation, which originated from a different part of the Federal Food, Drug, and Cosmetic Act (21 USC 360e-3), to devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Breakthrough devices must also meet at least one of the following four criteria: (1) represents breakthrough technology; (2) no approved or cleared alternatives exist; (3) offers a significant advantage over existing approved or cleared alternatives; or (4) availability of the device is in the best interest of patients. The designation offers FDA guidance to sponsors during the development and prioritized review of their regulatory submissions.
- 2. See the 2014 guidance.
- 3. Changes to the withdrawal procedures for accelerated approval pathway may be coming later this year, as pending legislation to reauthorize FDA user fee amendments (i.e., the FDA Safety and Landmark Advancements Act) includes a provision on accelerated approval that would expedite the procedures the

- FDA can use to withdraw such approval.
- 4. These review times are set forth in the FDA's <u>Prescription Drug User Fee Act reauthorization performance goals</u>: In particular, the FDA's current target is to review and act on 90% of standard New Drug Application and Biologics License Application (BLA) submissions within 10 months and 90% of priority submissions within six months. The FDA's target times to review biosimilar BLAs are described in the FDA's <u>Biosimilar User Fee Act reauthorization performance goals</u>.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.

Key Contacts

| Natasha Leskovsek | nleskovsek@cooley.com |
|-------------------|-----------------------|
| Washington, DC | +1 202 728 7131 |
| Sonia Nath | snath@cooley.com |
| Washington, DC | +1 202 776 2120 |

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.